Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classement en actions #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Prix de l'action
$0.2483
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$2.30M
Changement (1 jour)
-3.39%
Changement (1 an)
-89.01%
Pays
US
Échange Ensysce Biosciences, Inc. (ENSC)

Catégorie

Healthcare
Nombre d'actions en circulation pour Ensysce Biosciences, Inc. (ENSC)
Nombre d'actions en circulation au June 2026: 13.04M
Selon les derniers rapports financiers et le cours de l'action de Ensysce Biosciences, Inc., le nombre actuel d'actions en circulation est de 13.04M. À la fin de December 2023, l'entreprise avait 2.26M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Ensysce Biosciences, Inc. (ENSC) de 2017 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
2026 (TTM) 13.04M 646.17%
2024 1.75M -22.84%
2023 2.26M 1,158.25%
2022 179.93K 114.16%
2021 84.02K -98.12%
2020 4.46M -26.81%
2019 6.09M 1.42%
2018 6.01M 0.37%
2017 5.98M 0.00%
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 1,847.74%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 2,937.83%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M 377.04%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 3,573.87%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH